Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ATHA | Athira Pharma, Inc. | 2025-10-30 15:10:04 | 4.17 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATHA | 0001620463 | Athira Pharma, Inc. | US04746L2034 | 529900CSS4S4X8VY5C81 | 453368487 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | — | 18706 NORTH CREEK PARKWAY, SUITE 104 | BOTHELL | WA | 98011 | UNITED STATES | US | (425) 620-8501 | 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011 | 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011 | M3 Biotechnology, Inc. | — | 2011 | — | — | http://www.athira.com | 86,000,000 | 39,439,326 | 39,439,326 | Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. | 2025-10-30 17:27:28 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 86,000,000 | -10,300,000 | -10.6957 | 39,042,445 | 715,793 | 1.8676 |
| 2023 | 96,300,000 | -2,700,000 | -2.7273 | 38,326,652 | 382,462 | 1.008 |
| 2022 | 99,000,000 | -229,300,000 | -69.8447 | 37,944,190 | 320,132 | 0.8509 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Mark Worthington | Corporate Secretary, Chief Compliance Officer, General Counsel | 2024 | 450,000 | 0 | 49,489 | 207,000 | 24,523 | 1,337,509 |
| Andrew Gengos | Chief Financial Officer, Chief Business Officer | 2024 | 365,615 | 0 | 0 | 0 | 370,593 | 1,459,708 |
| Mark Litton | Chief Executive Officer, President | 2024 | 625,000 | 0 | 138,353 | 395,313 | 25,085 | 3,175,009 |
| Kevin Church | Chief Scientific Officer | 2024 | 450,000 | 0 | 49,489 | 207,000 | 23,085 | 1,336,071 |
| Rachel Lenington | Chief Operating Officer, Chief Development Officer | 2024 | 376,923 | 0 | 0 | 0 | 447,969 | 1,600,070 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 26 |
| 2023 | 67 |
| 2022 | 64 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | 0 | 0 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 70,682,000 | 93,790,000 | 61,464,000 |
| General And Administrative Expenses | 26,093,000 | 33,304,000 | 32,552,000 |
| Operating Expenses | 100,902,000 | 125,466,000 | 104,016,000 |
| Operating Income | -100,902,000 | -125,466,000 | -104,016,000 |
| Net Income | -96,940,000 | -117,672,000 | -95,639,000 |
| Earnings Per Share Basic | -2.52 | -3.09 | -2.53 |
| Earnings Per Share Diluted | -2.52 | -3.09 | -2.53 |
| Weighted Average Shares Outstanding Basic | 38,480,875 | 38,020,182 | 37,733,240 |
| Weighted Average Shares Outstanding Diluted | 38,480,875 | 38,020,182 | 37,733,240 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 48,438,000 | 90,584,000 | 95,966,000 |
| Marketable Securities Current | 2,837,000 | 56,835,000 | 104,378,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 54,841,000 | 154,729,000 | 207,533,000 |
| Marketable Securities Non Current | — | — | 44,829,000 |
| Property Plant And Equipment | 2,444,000 | 3,388,000 | 4,053,000 |
| Other Assets Non Current | 55,000 | 448,000 | 55,000 |
| Total Assets Non Current | 3,938,000 | 5,516,000 | 50,620,000 |
| Total Assets | 58,779,000 | 160,245,000 | 258,153,000 |
| Accounts Payable | 319,000 | 129,000 | 2,501,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 12,402,000 | 18,343,000 | 8,604,000 |
| Total Liabilities Current | 13,135,000 | 28,840,000 | 21,431,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 803,000 | 1,217,000 | 1,585,000 |
| Total Liabilities | 13,938,000 | 30,057,000 | 23,016,000 |
| Common Stock | 4,000 | 4,000 | 4,000 |
| Retained Earnings | -406,146,000 | -309,206,000 | -191,534,000 |
| Accumulated Other Comprehensive Income | 1,000 | -349,000 | -1,956,000 |
| Total Shareholders Equity | 44,841,000 | 130,188,000 | 235,137,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 970,000 | 969,000 | 845,000 |
| Share Based Compensation Expense | 11,049,000 | 10,623,000 | 10,606,000 |
| Other Non Cash Income Expense | -7,000 | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | -1,628,000 | 1,628,000 | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -5,751,000 | 7,367,000 | 2,101,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -97,170,000 | -100,753,000 | -72,469,000 |
| Purchases Of Marketable Securities | 14,134,000 | 27,671,000 | 95,288,000 |
| Sales Of Marketable Securities | 68,997,000 | 123,064,000 | 154,093,000 |
| Acquisition Of Property Plant And Equipment | 33,000 | 304,000 | 1,141,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 54,830,000 | 95,089,000 | 57,664,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 194,000 | 493,000 | 654,000 |
| Change In Cash | -42,146,000 | -5,171,000 | -14,151,000 |
| Cash At End Of Period | 48,438,000 | 90,584,000 | 95,966,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -2.52 | -3.09 | -2.53 |
| Price To Earnings Ratio | -2.3282 | -7.8641 | -12.5296 |
| Earnings Growth Rate | -18.4466 | 22.1344 | — |
| Price Earnings To Growth Ratio | 0.1262 | -0.3553 | — |
| Book Value Per Share | 1.1653 | 3.4242 | 6.2316 |
| Price To Book Ratio | 5.0348 | 7.0966 | 5.087 |
| Ebitda | -95,970,000 | -116,703,000 | -94,794,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 26,000 | 304,000 | 1,141,000 |
| Free Cash Flow | -97,196,000 | -101,057,000 | -73,610,000 |
| Return On Equity | -2.1619 | -0.9039 | -0.4067 |
| One Year Beta | 1.5664 | 1.2878 | 1.3519 |
| Three Year Beta | 1.3561 | 1.3421 | 1.3483 |
| Five Year Beta | 1.3523 | 1.3331 | 1.3483 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Renninger Robert | SVP, Finance and Accounting | 2025-07-01 | 2,897 | D | 109,186 |
| Worthington Mark | General Counsel and CCO | 2025-07-01 | 8,526 | D | 111,875 |
| San Martin Javier | CHIEF MEDICAL OFFICER | 2025-07-01 | 10,842 | D | 71,665 |
| Litton Mark James | Director, President and CEO | 2025-07-01 | 25,123 | D | 325,802 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 2025-07-01 | 8,526 | D | 168,901 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Christopher L. Jacobs | 2023-01-20 | NY27 | Purchase | 2022-12-12 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-12-12 | NY27 | Sale | 2022-11-08 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2022-09-09 | NY27 | Purchase | 2022-07-18 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| American Capital Advisory, LLC | 2025-09-30 | 828 | 200 | 4.14 |
| McIlrath & Eck, LLC | 2025-09-30 | 339 | 82 | 4.1341 |
| Global Retirement Partners, LLC | 2025-09-30 | 215 | 52 | 4.1346 |
| Simplify Asset Management Inc. | 2025-09-30 | 618,015 | 149,279 | 4.14 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 18,030 | 60,100 | 0.3 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 452,018 | 136,509.44 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 452,018 | 136,509.44 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | ETF Shares | VXF | 452,018 | 136,509.44 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Shares | VIEIX | 452,018 | 136,509.44 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Admiral Shares | VEXAX | 452,018 | 136,509.44 | 0.0001 |